KR20150042529A - Fermented ballonflower composition having excellent anti-inflammatory and anti-oxidant activity and manufacturing method thereof - Google Patents
Fermented ballonflower composition having excellent anti-inflammatory and anti-oxidant activity and manufacturing method thereof Download PDFInfo
- Publication number
- KR20150042529A KR20150042529A KR20130121286A KR20130121286A KR20150042529A KR 20150042529 A KR20150042529 A KR 20150042529A KR 20130121286 A KR20130121286 A KR 20130121286A KR 20130121286 A KR20130121286 A KR 20130121286A KR 20150042529 A KR20150042529 A KR 20150042529A
- Authority
- KR
- South Korea
- Prior art keywords
- mushroom
- fermentation
- fermented
- bellflower
- mycelium
- Prior art date
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 198
- 241000332371 Abutilon x hybridum Species 0.000 claims description 55
- 238000000855 fermentation Methods 0.000 claims description 43
- 230000004151 fermentation Effects 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 41
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 27
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 27
- 235000008434 ginseng Nutrition 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 206010061218 Inflammation Diseases 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims 3
- 241000252233 Cyprinus carpio Species 0.000 claims 1
- 244000000626 Daucus carota Species 0.000 claims 1
- 235000002767 Daucus carota Nutrition 0.000 claims 1
- 244000273928 Zingiber officinale Species 0.000 claims 1
- 235000006886 Zingiber officinale Nutrition 0.000 claims 1
- 235000008397 ginger Nutrition 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 6
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract description 5
- 208000027866 inflammatory disease Diseases 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 240000003582 Platycodon grandiflorus Species 0.000 abstract 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 47
- 240000004371 Panax ginseng Species 0.000 description 24
- 239000000469 ethanolic extract Substances 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 11
- 208000002874 Acne Vulgaris Diseases 0.000 description 10
- 206010000496 acne Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 240000008397 Ganoderma lucidum Species 0.000 description 6
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 241001165494 Rhodiola Species 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- -1 t Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 2
- APTNOIWSCDBIAS-UHFFFAOYSA-N 5,10,11-trihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1C(O)C(O)C(CO)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C APTNOIWSCDBIAS-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000190633 Cordyceps Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 244000274050 Platycodon grandiflorum Species 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241001072256 Boraginaceae Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 241000282988 Capreolus Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- MZNYWPRCVDMOJG-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine dihydrochloride Chemical compound [Cl-].[Cl-].C1=CC=C2C([NH2+]CC[NH3+])=CC=CC2=C1 MZNYWPRCVDMOJG-UHFFFAOYSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- JUIYKRQGQJORHH-ZIIOQTAFSA-N Rhamnazin 3-rutinoside Natural products O(C[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](OC2=C(c3cc(OC)c(O)cc3)Oc3c(c(O)cc(OC)c3)C2=O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 JUIYKRQGQJORHH-ZIIOQTAFSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 1
- 229960001669 kinetin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000024001 sorocarp development Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/02—Antioxidant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물 및 그의 제조방법에 관한 것으로 특히, 식용과 약용으로 국내에서 널리 사용되어 온 도라지를 버섯균사체로 발효시켜 추출한 것으로서, 버섯균사체로의 발효에 의하여 특히 항염 및 항산화 활성을 높인 도라지 버섯균사체 발효 조성물 및 그의 제조방법에 관한 것이다. The present invention relates to a fermented composition of Mycobacterium tuberculosis having excellent anti-inflammatory and antioxidant activity and a method of producing the same. Particularly, the present invention relates to a method of fermenting a mycelia of mushroom mycelia, And particularly to a fermented composition of mycelium of Doraji mushroom having enhanced anti-inflammatory and antioxidant activity and a method for producing the same.
염증성 질환에는 여드름과 아토피성 피부염이 대표적이라 할 수 있다.Inflammatory diseases include acne and atopic dermatitis.
여드름은 피지 샘(모발과 피부의 보습막을 형성하는 피지를 생산)과 모낭(털을 자라게 하는 피부 속 작은 구조)에 발생하는 흔한 염증성 피부 질환으로, 일반적으로 사춘기에 시작되며, 사춘기 청소년의 약 80% 이상 경험한다. 그렇다고 성인이 되면 없어지는 것이 아니라 평생에 걸쳐 발생되는 질환이다. 여드름 발생의 정확한 원인은 아직 명확하게 밝혀져 있지 않으며, 여러 가지 복합적인 원인으로 알려져 있다. 일반적으로 사춘기에 여드름 발생이 증가하는 이유는 안드로겐 호르몬이라는 남성 호르몬이 피지 샘을 자극하여 과도한 피지분비를 유도하기 때문이다. 모낭 내에 상주하는 균 중 특히 혐기성 피부 상재균인 프로피오니오니박테리움 아크네스(Propionibacterium acnes)는 지방분해 효소(lipase)를 분비하여 피지 중 중성지방(Triglyceride)을 유리지방산(Free Fatty Acid; FFA)와 글리세롤(Glycerol)로 분해한다. 분해된 물질 중 FFA와 각종 저분자 물질들의 자극에 의한 염증 반응이 여드름의 원인으로 알려져 있다. 그리고 가족력에 의한 유전적 요소는 정확한 유전 양식이 아직까지 보고되지 않고 있다. 여드름을 유발하는 그 밖의 요인으로는 유분이 많은 화장품의 사용, 습도, 과도한 땀 등이 있다. 여드름은 음식이나 나쁜 위생 상태와 연관이 없으며, 지나치게 잦은 세안은 오히려 여드름을 악화시킬 수 있다. 동양에서는 예로부터 염증과 알레르기성 피부질환 등의 치료 시, 당귀, 자초근, 감초, 지실, 작약, 황기, 황금, 유근피, 진피, 황련, 도라지, 오가피 등과 같은 한방약재를 사용하여 치료하였는데, 최근 여드름과 아토피 피부질환의 증가로 특히 주목받고 있다. Acne is a common inflammatory skin disease that occurs in sebaceous glands (sebaceous glands that form the moisturizing membrane of hair and skin) and hair follicles (small structures in the skin that grow hair), usually beginning puberty, %. It does not disappear when it becomes an adult, but it is a disease that occurs throughout life. The exact cause of acne has not been clarified yet and is known to be a complex cause. Generally, the reason for the increase of acne in adolescence is because the male hormone called androgen hormone stimulates the sebaceous glands and induces excessive sebum secretion. Propionibacterium acnes , which is an anaerobic skin microorganism, especially, resides in the hair follicle, secretes lipase and releases triglyceride in free fatty acid (FFA) And glycerol (Glycerol). Among the degraded substances, the inflammation reaction caused by the stimulation of FFA and various low molecular substances is known to be the cause of acne. And genetic factors due to family history have not yet been reported. Other factors that cause acne include the use of oily cosmetics, humidity, and excessive sweating. Acne is not associated with food or bad hygiene, and too frequent cleansing can make acne worse. In Oriental medicine, herbal medicines such as Angelica gigas, Glycyrrhiza, Licorice, Glycyrrhiza, Peony, Hwanggi, Golden, Root, Dermatophyte, Rhodiola, Bellflower and Ogapi were used for treatment of inflammation and allergic skin diseases. Recently, acne And atopic skin disease.
염증은 세포상해를 유발하는 다양한 자극에 대하여 혈관을 가지고 있는 살아있는 조직의 유해물질을 파괴, 희석 또는 국소화해서 손상조직을 정상화하는 과정이다. 염증은 자극에 의해서 혈압이 높아지므로 혈관 투과성이 증가하여 혈관 바깥조직으로 백혈구와 체액이 축적되어 주로 피부기관에서 발생되는 염증성 질환은 면역계를 자극하고 과로와 스트레스에 의해서 더 심화되는 경향이 있는 것으로 알려지고 있다. 염증유발인자들로 알려진 히스타민, 키니, 시토키니 등과 인터루킨-10(IL-10)은 연관되어 있고, 특히 도움 T세포(helper T cell)과 조절 T세포(regulatory T cell)는 자가면역질환(알레르기, 아토피, 두드르기, 관절염, 백선 등)과 밀접한 관련이 있다. 도움 T세포는 세포독성이나 식세포 작용이 없고, 다른 면역 세포들의 활성화와 지휘 역할을 한다. 도움 T세포의 Th1은 식세포작용을 유도시키고, Th2는 염증을 유발시킨다. 인터루킨-10을 Th1이 분비되어 자기조직을 공격하는 면역세포를 억제시켜 면역관용을 유도한다. 인터루킨-13은 Th2 세포에 의해 만들어지는 싸이토카인으로, 천식과 알레르기 등과 매우 밀접한 관련이 있고, Th2 세포의 분화와도 밀접한 관련이 있어 최근 치료제 분야에서 IL-13의 기능 억제 연구가 시도되고 있다. 그러나 아직 항히스타민제, 스테로이드제 등으로 일시적으로 증세 완화시켜 줄 뿐이며, 근원적인 예방 또는 치료방법이 알려져 있지 않다. 천연소재 중 해바라기 씨, 녹차, 신선초, 시금치 등에서 IL-13의 생산을 억제하는 물질이 함유되어 있다고 보고되고 있으나, 이를 산업화하기에는 그 효능이 미미하다. 따라서 염증 등과 같은 자가면역질환의 근원적인 예방과 치료에 효과가 있는 치료제의 개발이 요구되고 있다. Inflammation is the process of normalizing damaged tissue by destroying, diluting or localizing harmful substances in living tissues that have blood vessels in response to various stimuli that cause cytotoxicity. Inflammation increases the blood pressure due to stimulation, so that the vascular permeability increases and leukocytes and body fluids accumulate outside the blood vessels. Inflammatory diseases mainly occurring in the skin organs tend to be exacerbated by the immune system, overwork and stress. ought. (IL-10) and histamine, kinetin and cytokinin, which are known as inflammation inducers, are associated with helper T cells and regulatory T cells, especially autoimmune diseases , Atopy, tingling, arthritis, ringworm, etc.). Helper T cells do not have cytotoxic or phagocytotic effects, and act as a conduit and leader of other immune cells. Helps T cells in Th1 induce phagocytosis, and Th2 in inflammation. Interleukin-10 induces immune tolerance by inhibiting immune cells that secrete Th1 and attack self-organization. Interleukin-13 is a cytokine produced by Th2 cells, closely related to asthma and allergies, and closely related to the differentiation of Th2 cells, and recent attempts have been made to inhibit the function of IL-13 in the therapeutic field. However, antihistamines, steroids, and still temporarily alleviate the symptoms, the underlying prevention and treatment methods are unknown. Among the natural materials, sunflower seeds, green tea, fresh chestnut, and spinach have been reported to contain substances that inhibit the production of IL-13, but their effect is insignificant for industrialization. Therefore, it is required to develop a therapeutic agent which is effective for prevention and treatment of autoimmune diseases such as inflammation.
이에 본 발명자들은 부작용이 없고, 항염증 활성이 있는 새로운 천연물 조성물을 개발하고자 예의 노력한 결과, 도라지나 그의 단순 추출물에 비해, 도라지 발효물, 특히 도라지 버섯균사체 발효물이 우수한 항염증 효과가 있음을 확인하고 본 발명을 완성하였다.Therefore, the present inventors have made intensive efforts to develop a new natural composition having no anti-inflammatory activity and have no side effects. As a result, it has been found that the fermented product of the bellflower, especially the bellflower mycelium, And completed the present invention.
본 발명에 따른 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물은, 도라지에 버섯균사체를 접종시켜 발효시킨 것을 특징으로 하며, 특히 상기 도라지의 발효에 사용되는 버섯균사체는 차가버섯, 상황버섯, 꽃송이버섯, 송이버섯, 표고버섯, 잎새버섯, 목이버섯, 새송이버섯, 팽이버섯, 양송이버섯, 구름버섯, 느타리버섯, 영지버섯, 동충하초, 복령, 저령, 치마버섯, 노루궁뎅이버섯으로부터 선택되는 버섯의 균사체들로 이루어지는 군으로부터 선택되는 1종 이상인 것을 특징으로 한다. The mushroom mycelium fermented composition having excellent anti-inflammation and antioxidant activity according to the present invention is characterized in that the mushroom mycelium is inoculated into the mushroom by inoculating the mushroom mycelia into the mushroom. In particular, the mushroom mycelium used for the fermentation of the mushroom Mushroom mycelia selected from mushroom, mushroom, mushroom, shiitake, mushroom, mushroom, mushroom, mushroom, mushroom mushroom, mushroom mushroom, mushroom mushroom, mushroom mushroom, gentian mushroom, caterpillar fungus, And at least one selected from the group consisting of
또한, 본 발명에 따른 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법은, (1) 도라지를 90 내지 120℃의 범위 이내의 온도에서 30 내지 90분간 증자시키는 증자단계; (2) 상기 증자된 도라지를 10 내지 50℃의 범위 이내의 온도까지 냉각시키는 냉각단계; 및 (3) 상기 증자되어 냉각된 도라지 90 내지 99중량%에 버섯균사체 1 내지 10중량%를 접종시킨 후, 15 내지 40℃의 범위 이내의 온도에서 10 내지 30일간 발효시키는 발효단계;를 포함하며, 특히, 상기 발효단계에서 사용되는 상기 버섯균사체는 차가버섯, 상황버섯, 꽃송이버섯, 송이버섯, 표고버섯, 잎새버섯, 목이버섯, 새송이버섯, 팽이버섯, 양송이버섯, 구름버섯, 느타리버섯, 영지버섯, 동충하초, 복령, 저령, 치마버섯, 노루궁뎅이버섯으로부터 선택되는 버섯의 균사체들로 이루어지는 군으로부터 선택되는 1종 이상인 것을 특징으로 한다. Also, a method for preparing a fermented mushroom mycelia composition having excellent anti-inflammatory and antioxidative activity according to the present invention comprises: (1) a step of growing bellflower at a temperature within a range of 90 to 120 ° C for 30 to 90 minutes; (2) a cooling step of cooling the expanded bellflower to a temperature within a range of 10 to 50 캜; And (3) a fermentation step of inoculating 1 to 10% by weight of mushroom mycelia to 90 to 99% by weight of the thus-cooled and cooled broth, and fermenting the mixture at a temperature within a range of 15 to 40 ° C for 10 to 30 days In particular, the mushroom mycelium used in the fermentation step may be selected from the group consisting of mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, And mushrooms selected from the group consisting of mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, and mushroom.
본 발명에 따르면, 식용과 약용으로 국내에서 널리 사용되어 온 도라지를 버섯균사체로 발효시켜 추출한 것으로서, 버섯균사체로의 발효에 의하여 특히 항염 및 항산화 활성을 높인 도라지 버섯균사체 발효 조성물 및 그의 제조방법을 제공하는 효과가 있다. 특히, 본 발명에 따라 제조된 도라지 버섯균사체 발효 추출물은 대식세포 RAW264.7의 산화질소 생성능을 억제하는 활성을 가져, 도라지 버섯균사체 발효물을 유효성분으로 함유하는 염증성 질환의 예방 및 치료를 위한 식의약조성물로 이용될 수 있는 효과가 있다.According to the present invention, there is provided a fermented composition of Doraji-mushroom mycelia which is obtained by fermenting Doraji, which has been widely used in Korea for edible and medicinal purposes, by fermentation into mushroom mycelium, . In particular, the fermented extract of Rhodiola mushroom mycelium produced according to the present invention has an activity of inhibiting the nitric oxide production ability of macrophage RAW264.7, and is useful for the prevention and treatment of inflammatory diseases containing the fermented product of Rhodiola mushroom mycelia as an active ingredient There is an effect that it can be used as a pharmaceutical composition.
도 1은 본 발명에 따른 도라지 버섯균사체 발효 추출물을 마우스 유래의 RAW264.7 대식세포(Macrophage Cell)의 산화질소(NO) 생성에 미치는 영향을 나타낸 그래프이다. 도 1에서 데이터는 평균±표준편차((n=3), (p<0.05))이다.
도 2는 본 발명에 따른 도라지 발효 추출물의 항산화 활성 시험 결과를 나타낸 그래프이다. 도 2는 추출 용매에 따른 비-발효 도라지와 버섯균사체 발효 도라지의 항산화(DPPH) 활성을 나타내고 있다. 여기에서 DW는 비-발효 도라지의 멸균증류수 추출물, F-DW는 본 발명에 따른 도라지 버섯균사체 발효물의 멸균증류수 추출물, E50은 비-발효 도라지의 50% 에탄올 추출물, F-E50은 본 발명에 따른 도라지 버섯균사체 발효물의 50% 에탄올 추출물, E100은 비-발효 도라지의 100% 에탄올 추출물, F-E100은 본 발명에 따른 도라지 버섯균사체 발효물의 100% 에탄올 추출물을 나타내고 있다.
도 3은 본 발명에 따른 도라지 발효물을 촬영한 사진이다.
도 4는 추출 용매에 따른 비-발효 인삼과 버섯균사체 발효 인삼의 항산화(DPPH) 활성을 나타내는 그래프이다.
도 5는 본 발명에 따른 인삼의 버섯균사체 발효물을 촬영한 사진이다.FIG. 1 is a graph showing the effect of the fermentation extract of Rhodiola mushroom mycelium according to the present invention on the production of nitric oxide (NO) in RAW264.7 macrophage cells derived from mice. In Figure 1, the data are mean ± standard deviation ((n = 3), (p <0.05)).
FIG. 2 is a graph showing the results of antioxidative activity tests of the borax fermented extract according to the present invention. Fig. 2 shows the antioxidative (DPPH) activities of non-fermented Dorago and mushroom mycelial fermented Dorrass according to the extraction solvent. Wherein F-DW is the sterilized distilled water extract of the fermented product of the mushroom mycelium according to the present invention, E50 is the 50% ethanol extract of the non-fermented broth and F-E50 is the distilled water extract of the non- 50% ethanol extract of the fermented mycelia of mycelia of Doraji mushroom, 100% ethanol extract of non-fermented Doradha as E100, and F-E100 as 100% ethanol extract of the fermented Mycelium of Doraji mushroom according to the present invention.
FIG. 3 is a photograph of a borage broth according to the present invention. FIG.
FIG. 4 is a graph showing antioxidant (DPPH) activity of non-fermented ginseng and fermented ginseng of mushroom mycelium according to the extraction solvent.
5 is a photograph of a fermented product of mushroom mycelium of ginseng according to the present invention.
이하, 본 발명의 구체적인 실시예를 첨부한 도면을 참조하여 상세히 설명한다.Hereinafter, specific embodiments of the present invention will be described in detail with reference to the accompanying drawings.
본 발명에 따른 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물은 도라지에 버섯균사체를 접종시켜 발효시킨 것을 특징으로 한다.The fermented composition of bellflower mushroom mycelium having excellent anti-inflammation and antioxidant activity according to the present invention is characterized in that the bellflower is fermented by inoculating mushroom mycelium.
상기 도라지(Platycodon grandiflorum)는 초롱꽃과에 속하는 여러해살이 풀 또는 그 뿌리를 의미한다. 도랒이라 줄여 부르기도 하며, 한자어로는 길경(桔梗), 백약(白藥), 경초(梗草), 고경(苦梗)이라고 한다. 도라지는 온대지방의 평지 및 해발 1,000m 정도에 이르는 산지의 양지바른 곳에서 자란다. 도라지는 한국, 중국 및 일본의 산간지방에서 야생하는 다년생 초본으로 더덕과 함께 일반식용으로 널리 이용되고 있으며, 기호품으로도 상당한 호평을 받는 식품일 뿐 아니라, 진해, 거담 등의 약효가 있다고 고래부터 식이요법이 전해지며, 더덕, 인삼과 함께 한방약재로 쓰이고 있다. 또한, 도라지의 뿌리에는 인삼의 주요 성분인 사포닌이 함유되어 있어, 약재로 쓰이기도 한다. 도라지의 지질은 점성과 독특한 향기를 가지고 있으며, 포화지방산이 불포화지방산보다 많은 것이 특색이다. 도라지는 식용으로서 뿐만 아니라 약용으로도 널리 사용되었다. 문헌기록 중 ‘향약집성방(鄕藥集成方)’에 처음 나타나는데, “맛이 맵고 온화하며 독이 약간 있다. 2 내지 8월에 뿌리를 캐며, 햇볕에 말린 것은 인후통을 잘 다스린다”고 하였다. ‘동의보감’에서는 “성질이 약간 차고, 맛은 맵고 쓰며, 약간 독이 있다. 허파, 목, 코, 가슴의 병을 다스리고 벌레의 독을 내린다”고 하였다. ‘일화본초(日華本草)’에서는 허파의 화농증을 다스리고 농을 배설시킨다고 하였다. 현재 민간처방에서 감기, 기침, 냉병, 복통, 부스럼, 설사, 산후병, 부인병, 불면증, 인후카타르, 편도선염, 기관지염, 월경통, 이질, 진해거담, 위산과다, 이뇨, 보혈에 효과가 있다고 한다. 도라지의 잎은 발이 부르튼 데 유용하며, 도라지와 수탉을 삶아 먹으면 대하증이 치료된다고 한다. 치통, 설사 때는 뿌리의 껍질을 벗기고 기름에 지져 먹으면 나으며, 피를 토할 때도 쓰인다고도 한다. 도라지는 다당류인 이눌린(inulin), 트리테르페노이드(triterpenoids), 트리테르펜(triterpene), 사포닌(saponins)인 플라티코딘(platicodin), 플라티코디게닌(platycodigenin), 폴리갈락신(polygalacin) 등이 다량 함유되어 있어, 면역증진 및 항염증, 항궤양, 피부진정효과, 해열, 혈액순환, 해독, 항균 등의 다양한 기능성이 있는 것으로 알려지고 있다. 관절염과 폐농양, 부스럼에는 옛날부터 치료약으로 처방되어 왔다. 특히 도라지 뿌리는 염증을 가라앉히고 체내에 나쁜 피를 배출하는 효능이 있어 도라지 달인 물로 세수를 하거나 여드름 부위에 발라주면 과도한 피지분비를 억제하고, 울긋불긋한 염증을 진정시킬 수 있는 것으로 알려져 있다. Platycodon grandiflorum refers to a perennial plant belonging to the genus L. or its root. It is also called 랒 랒 줄 줄 줄.......................... Bellflower grows in a sunny place in the mountainous area of the temperate plain of the temperate region and the altitude of 1,000m above sea level. Doraji is a perennial herb that is wild in the mountainous regions of Korea, China and Japan. It is widely used for general food along with dodec, and it is not only a food that is well received as a favorite product but also has a medicinal effect such as Jinhae, Therapy is given, and it is used as a herbal medicine along with roe deer and ginseng. In addition, saponin, which is the main ingredient of ginseng, is contained in the root of the bellflower, and it is also used as a medicinal product. Bellflower lipids have a viscosity and distinctive aroma, and saturated fatty acids are more characteristic than unsaturated fatty acids. Bellflower has been widely used not only as edible but also as a medicinal product. In the document, it appears for the first time in the "鄕 药 集成 方" (鄕 药 集成 方), "The taste is mild, mild, and slightly poisonous. It takes root in February and August, and drying in the sun is good for sore throat. " In 'Dongbokgop', "the quality is a little bit cold, the taste is spicy, and a little poisonous. Lungs, neck, nose, and chest, and poison the worms. " In the "Ilhwa Honsha", it was said that the lung disease was controlled and excreted in the lungs. It is said that it is effective in the current private prescription for cold, cough, cold disease, abdominal pain, swelling, diarrhea, postpartum illness, women's disease, insomnia, throat qataritis, bronchitis, dysmenorrhea, dysentery. The bellflower leaves are useful for the feet to bite, and the bellflower and the cock are said to be cured when boiled and eaten. Toothache and diarrhea are peeled off from the roots, eaten in oil, eaten, and used in pouring blood. Platycodon is a polysaccharide that contains polysaccharides such as inulin, triterpenoids, triterpene, saponins, platicodin, platycodigenin, polygalacin, etc. Is known to have various functions such as immunity enhancement and anti-inflammation, anti-ulcer, skin soothing effect, antipyretic, blood circulation, detoxification, and antibacterial activity. Arthritis, lung abscess and swelling have long been prescribed as remedies. In particular, the bellflower root has the effect of sinking inflammation and discharging bad blood into the body, and it is known that it can suppress excessive sebum secretion and calm the irritated inflammation by applying water to the acne area with water as a bellflower.
본 발명에서는 기존의 버섯 추출액을 우려내어 그 물에 유산균을 발효하고 이를 증자한 더덕을 넣어 숙성시키는 공정과는 달리 직접 도라지에 버섯균사체를 도포하는 것에 의하여 도라지의 섬유질을 기질로 한 버섯균사체의 발육을 유도함으로써 외부의 탄소원 제공없이 균사체를 확보하고, 버섯균사체의 확보 뿐만 아니라 도라지의 다당류의 저분자 올리고당화 등의 생물전환이 이루어지는 특징을 가진다. 이러한 기본적인 원리를 바탕으로 도라지와 버섯의 약리성분과 영양성분을 동시에 만족시킨 새로운 소재를 개발함으로써 도라지 등 섬유질이 높은 근채류(산채류) 등의 세포벽 구성 성분인 섬유질을 버섯의 기질로 제공하며, 세포벽을 와해시켜 도라지의 약리 성분의 추출을 극대화하고, 유용성분의 분자구조를 분해시켜 인체 흡수율과 이용률을 상승시켜 발효산물에 의한 부가적 기능성을 갖도록 한 점에 특징이 있는 것이다.In the present invention, unlike the conventional process of fermenting lactic acid bacteria into the water and aging the fermented lactic acid bacterium, the mushroom mycelium is directly applied to the bellflower to develop the mushroom mycelium with the fiber of the bellflower as a substrate Thereby securing the mycelium without providing an external carbon source and securing the mushroom mycelium as well as biological conversion such as low molecular weight oligosaccharide of the polysaccharide of the bellflower. Based on this basic principle, we have developed a new material that satisfies the pharmacological and nutritional components of bellflower and mushroom simultaneously, providing fiber as a substrate component of mushrooms, such as flower seeds (mountain vegetables) The present invention is characterized in that the extraction of the pharmacological components of the bellflower is maximized and the molecular structure of the useful component is decomposed to increase the absorption rate and the utilization rate of the human body so as to have additional functionalities by fermentation products.
상기 도라지의 발효에 사용되는 상기 버섯균사체는 차가버섯, 상황버섯, 꽃송이버섯, 송이버섯, 표고버섯, 잎새버섯, 목이버섯, 새송이버섯, 팽이버섯, 양송이버섯, 구름버섯, 느타리버섯, 영지버섯, 동충하초, 복령, 저령, 치마버섯, 노루궁뎅이버섯으로부터 선택되는 버섯의 균사체들로 이루어지는 군으로부터 선택되는 1종 이상인 것이 될 수 있다.The mushroom mycelium used for fermentation of the bellflower is selected from the group consisting of mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, Mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, and the like.
상기 버섯균사체의 버섯들 중 상기 영지버섯은 독성이 없고, 달고, 평하며, 심, 비, 폐, 간, 경을 보하고 피부윤택, 기억력 증진, 중추신경계에 작용진정, 진통, 기관지 및 장근육 이완, 강심, 콜레스테롤 강하, 혈압저하 기능을 가지며, 목질부후를 통해 성장한다. 자실체 형성을 위한 핵심 물질들을 균사체에 함유하고 있어 최근 산업적 응용이 높아지고 있다. 대표적으로 영양성분과 기능성이 풍부한 표고버섯은 페놀화합물, 단백다당체 등의 다양한 생리 활성물질을 균사체 내에 다량 함유하고 있음이 알려져 균사체만으로 이미 상품화가 이루어지고 있다. 그리고 건발효는 메주띄움에 관여하는 곰팡이의 발효와 상응한 부분도 있으나, 버섯의 발효과정에서 독특한 목질부후 특성에 따른 차별성이 존재하며, 특히 버섯 중 근권류에 속하는 송로, 복령 등과 일반식용 버섯인 표고, 팽이, 느타리, 양송이 그리고 약용버섯류인 영지, 상황, 차가 등이 이미 균사체배양이 검증되었거나 검증되고 있다. 상기 도라지 외에 오가피, 잔대, 인삼 또는 이들 중 2이상의 혼합물로 이루어지는 군으로부터 선택되는 한약재가 더 포함될 수 있다.Among the mushrooms of the mushroom mycelium, the Ganoderma mushroom has no toxicity, sweetness, flatness, abdomen, rain, lungs, liver and stomach, skin moisturizing, memory enhancement, central nervous system effect sedation, analgesia, Relaxation, heart rate, cholesterol lowering, blood pressure lowering function, and it grows after the woody part. Since mycelium contains the key substances for fruiting body formation, industrial application is increasing recently. It is known that shiitake mushrooms, which are rich in nutritional and functional properties, contain a large amount of various physiologically active substances such as phenolic compounds and protein polysaccharides in their mycelia, and thus they are already commercialized only by mycelia. In addition, the dry fermentation has a part corresponding to the fermentation of the fungus involved in the spreading, but there is a difference according to the characteristics of the unique woody part in the fermentation process of the mushroom. Especially, the tongue, Mycelium cultivation has already been verified or verified, such as altitude, top, oyster, mushroom, medicinal mushroom, manure, situation, and tea. In addition to the bellflower, the medicinal herb may be further selected from the group consisting of oranges, ginseng, ginseng, or a mixture of two or more thereof.
또한, 본 발명에 따른 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법은 (1) 도라지를 90 내지 120℃의 범위 이내의 온도에서 30 내지 90분간 증자시키는 증자단계; (2) 상기 증자된 도라지를 10 내지 50℃의 범위 이내의 온도까지 냉각시키는 냉각단계; 및 (3) 상기 증자되어 냉각된 도라지 90 내지 99중량%에 버섯균사체 1 내지 10중량%를 접종시키는 접종시킨 후, 15 내지 40℃의 범위 이내의 온도에서 10 내지 30일간 발효시키는 발효단계;를 포함함을 특징으로 한다.In addition, the method for preparing the bellflower mycelia fermentation composition having excellent anti-inflammatory and antioxidant activity according to the present invention comprises: (1) a step of growing bellflower at a temperature within a range of 90 to 120 ° C for 30 to 90 minutes; (2) a cooling step of cooling the expanded bellflower to a temperature within a range of 10 to 50 캜; And (3) a fermentation step of inoculating 1 to 10% by weight of the mushroom mycelium into 90 to 99% by weight of the frozen and cooled broth, followed by fermentation at a temperature within a range of 15 to 40 DEG C for 10 to 30 days; .
즉, 상기와 같은 본 발명의 목적을 달성하기 위하여, 본 발명은 도라지를 세척하고, 상기 세척한 도라지 90 내지 99중량%에 버섯균사체 1 내지 10중량%를 투입하여 혼합 도포하고, 상기 혼합 도포된 도라지를 발효시키고, 상기 발효에 의해 수득되는 발효물을 건조시키는 것을 포함하여, 도라지를 버섯균사체로 발효시키는 것을 특징으로 한다.That is, in order to accomplish the object of the present invention as described above, the present invention provides a method of washing a bellflower, mixing and spraying 1 to 10% by weight of mushroom mycelia with 90 to 99% by weight of the washed bellflower, Comprising fermenting the bellflower, and drying the fermented product obtained by the fermentation, wherein the bellflower is fermented into a mushroom mycelium.
이하 본 발명의 방법의 하나의 구체예를 단계별로 한정하여 설명하면 다음과 같다.Hereinafter, one specific embodiment of the method of the present invention will be described as follows.
제1단계 : 도라지를 세척하는 공정Step 1: The process of washing the bellflower
본 발명에 따른 도라지 발효물의 제조에 사용되는 도라지는 건조 도라지든 생도라지든 그 형태가 특별히 한정되지 않으나, 되도록 표피를 제거하지 않은 생도라지를 선택하여 깨끗한 물에 세척한 후, 물기를 제거한다.The bellflower used in the production of the bellflower according to the present invention is not particularly limited as to whether the bellflower is dried or not. However, the bellflower without any epidermis is selected, washed with clean water, and then the water is removed.
제2단계 : 도라지를 증자하는 공정Step 2: The process of increasing the bellflower
상기 세척하여 물기를 제거한 도라지를 증자기를 활용하여 90 내지 120℃, 바람직하게는 100℃에서 30 내지 90분간, 바람직하게는 60분 이상 증자시킨다.The balloon with the water removed by washing is heated at 90 to 120 ° C, preferably 100 ° C for 30 to 90 minutes, preferably 60 minutes or more, using a booster.
제3단계 : 증자한 도라지를 냉각시키는 공정Step 3: Process of cooling the increased bellflower
상기 증자한 도라지를 10 내지 50℃, 바람직하게는 40℃로 냉각시킨다.The expanded bellflower is cooled to 10 to 50 캜, preferably to 40 캜.
제4단계 : 접종공정Step 4: Inoculation process
상기 도라지 90 내지 99중량％에 버섯균사체 1 내지 10중량％을 투입하여 혼합하되, 특히 도라지의 표면에 버섯균사체가 골고루 도포되도록 한다.1 to 10% by weight of mushroom mycelia is added to 90 to 99% by weight of the above-mentioned bellflower, and the mushroom mycelium is uniformly spread on the surface of the bellflower.
제5단계 : 발효공정Step 5: Fermentation process
상기 버섯균사체가 도포된 도라지를 15 내지 40℃에서, 10 내지 30일간 발효시킨다.The bellflower to which the mushroom mycelia is applied is fermented at 15 to 40 DEG C for 10 to 30 days.
상기 발효단계에서 상기 버섯균사체가 차가버섯, 상황버섯, 꽃송이버섯, 송이버섯, 표고버섯, 잎새버섯, 목이버섯, 새송이버섯, 팽이버섯, 양송이버섯, 구름버섯, 느타리버섯, 영지버섯, 동충하초, 복령, 저령, 치마버섯, 노루궁뎅이버섯으로부터 선택되는 버섯의 균사체들로 이루어지는 군으로부터 선택되는 1종 이상인 것이 될 수 있다.In the fermentation step, the mycelia of mushrooms are selected from the group consisting of mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, , Mycelium of mushrooms selected from the group consisting of mushroom, cherry mushroom, and mushroom mushroom.
또한, 상기 도라지 외에 오가피, 잔대, 인삼 또는 이들 중 2이상의 혼합물로 이루어지는 군으로부터 선택되는 한약재가 더 포함될 수 있다.In addition to the bellflower, the medicinal herb may be further selected from the group consisting of acacia, ginseng, ginseng, or a mixture of two or more thereof.
상기 발효단계 이후에, 상기 발효단계에서 수득되는 발효물을 건조시키는 건조단계가 더 포함될 수 있다. 상기 건조단계는 동결건조 또는 감압건조 방식으로 수행될 수 있으며, 이러한 동결건조나 감압건조 방법 및 그러한 방법을 수행하는 데 필요한 장치들은 모두 당업자에게는 국내외 유수의 제조업자들에 의하여 상용적으로 제공되는 동결건조장치나 감압건조장치를 구입하여 사용할 수 있으며, 또한 제조업자의 지시서에 따라 적절한 건조공정을 수행할 수 있음은 당업자에게는 이해될 수 있는 것이다.After the fermentation step, a drying step of drying the fermentation product obtained in the fermentation step may be further included. The drying step may be performed by lyophilization or vacuum drying. All of the lyophilization and vacuum drying methods and apparatuses necessary for carrying out such a method are known to those skilled in the art as freezing It should be understood by those skilled in the art that a drying device or a vacuum drying device can be purchased and used, and an appropriate drying process can be performed according to the manufacturer's instructions.
상기 발효단계 이후에, 상기 발효단계에서 수득되는 발효물을 물 또는 탄소수 1 내지 4의 저급알코올로 추출하는 추출단계가 더 포함될 수 있으며, 상기 추출단계에서 사용되는 저급알코올은 30 내지 100중량%의 알코올을 포함하는 저급알코올, 특히 바람직하게는 탄소수가 2개인 에탄올이 될 수 있다.The fermentation step may further include an extraction step of extracting the fermentation product obtained in the fermentation step with water or a lower alcohol having 1 to 4 carbon atoms after the fermentation step, and the lower alcohol used in the extraction step may contain 30 to 100 wt% Lower alcohol containing alcohol, particularly preferably ethanol having 2 carbon atoms.
상기 냉각단계와 상기 발효단계 사이에서 상기 증자된 도라지를 파쇄하는 파쇄단계를 더 포함할 수 있으며, 상기 파쇄는 통상의 파쇄기 등을 이용하여 자동 기계작업 및/또는 수작업으로도 가능함은 당업자에게는 이해될 수 있는 것이다.The method of the present invention may further comprise a crushing step of crushing the donated bellflower between the cooling step and the fermentation step. It is to be understood by those skilled in the art that the crushing may be performed by an automatic machine using a conventional crusher or the like and / You can.
이하에서 본 발명의 바람직한 실시예 및 비교예들이 기술되어질 것이다.Hereinafter, preferred embodiments and comparative examples of the present invention will be described.
이하의 실시예들은 본 발명을 예증하기 위한 것으로서 본 발명의 범위를 국한시키는 것으로 이해되어져서는 안될 것이다.The following examples are intended to illustrate the invention and should not be construed as limiting the scope of the invention.
실시예 1Example 1
도라지 버섯균사체 발효물의 제조Preparation of Fermented Mycelium of Bellflower Mushroom
(1) 세척 공정(1) Cleaning process
생도라지 5㎏을 깨끗한 물로 세척한 후, 물기를 제거하였다.After washing 5 kg of raw broth with clean water, the water was removed.
(2) 증자 공정(2) The capital increase process
상기 세척하여 물기를 제거한 도라지를 증자기를 활용하여 100℃에서 60분간 증자시켰다.After washing with water and removing the water, the doner broth was heated at 100 ° C for 60 minutes using a booster.
(3) 냉각 공정(3) Cooling process
상기 증자한 도라지를 40℃로 냉각시켰다.The expanded broth was cooled to 40 캜.
(4) 혼합 공정(4) Mixing process
상기 냉각된 도라지 5㎏에 영지버섯 균사체 200g을 투입하여 혼합 도포시켰다.200 g of mycelia of Ganoderma lucidum was added to 5 kg of the cooled bellflower to be mixed.
(5) 발효 공정(5) Fermentation process
상기 버섯균사체가 도포 혼합된 도라지를 18℃에서 10일간 전발효시킨 후 24℃에서 10일간 후발효시켰다.The mushroom mycelia was coated and mixed and the mixture was pre-fermented at 18 ° C. for 10 days and then fermented at 24 ° C. for 10 days.
(6) 건조 공정(6) Drying process
상기 발효물을 동결건조기를 활용하여 건조시켰다.The fermented product was dried using a freeze dryer.
실시예 2Example 2
상기 실시예 1에서 수득된 도라지 발효물을 180메쉬 이하의 분말로 분쇄하여 물과 에탄올과 함께 교반 추출하여 도라지 버섯균사체 발효 추출물을 수득하였다.The seedlings obtained in Example 1 were pulverized with a powder having a size of 180 mesh or less and stirred with water and ethanol to obtain a fermented extract of Rhodiola mushroom mycelia.
실시예 3Example 3
도라지 대신 인삼을 사용한 것을 제외하고는 상기 실시예 1과 동일하게 수행하여 인삼의 영지버섯 발효 추출물을 수득하였다.The ginseng fermentation extract of Ganoderma lucidum was obtained in the same manner as in Example 1, except that ginseng was used instead of bellflower.
실시예 4Example 4
도라지 대신 인삼을 사용하고, 영지버섯 대신 동충하초를 사용한 것을 제외하고는 상기 실시예 1과 동일하게 수행하여 인삼의 동충하초 발효 추출물을 수득하였다.The ginseng fermented extract of ginseng was obtained by the same procedure as in Example 1, except that ginseng was used instead of bellflower, and ciceror was used instead of gingko mushroom.
실험예 1Experimental Example 1
대식세포 RAW264.7의 산화질소 생성능의 억제 실험Inhibition of nitric oxide production by macrophage RAW264.7
한국 세포주 은행(Korean Cell Line Bank)으로부터 마우스 RAW 264.7 대식세포(macrophage cell)를 구입하여 10％ 우태혈청(FBS; fetal bovine serum), 페니실린 G(penicillin G)(100IU/㎖), 스트렙토마이신(streptomycine)(100ug/㎖)을 포함한 DMEM 배지(미합중국 미주리주 세인트루이스 소재 시그마사(Sigma) 제품)에서 37℃, 5％ 이산화탄소를 유지하면서 배양하였다. 세포 수는 혈구계수기(hemocytometer)로 측정하였다. Mouse RAW 264.7 macrophage cells were purchased from the Korean Cell Line Bank and cultured with 10% fetal bovine serum (FBS), penicillin G (100 IU / ml), streptomycin ) (100 ug / ml) in DMEM medium (Sigma, St. Louis, Mo.) at 37 占 폚 while maintaining 5% carbon dioxide. Cell numbers were measured with a hemocytometer.
DMEM 배지에 배양된 마우스 RAW 264.7 대식세포를 배양액과 함께 96웰(well)에 180㎕를 넣고 2시간 동안 배양 후 시료를 20㎕씩 넣은 후 24시간 동안 배양시켰다. 배양 후, 배지를 제거하고, MTT(3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl- tetrazolium bromide; 시그마사 제품, PBS 내 5mg/㎖)를 200㎕ 첨가하여 4시간 더 배양시켰다. 4시간 후, 배지를 제거하고, 이때 미토콘드리아 디하이드로게나아제(dehydrogenase)에 의해 형성된 어두운 파란색 결정(dark blue crystal)을 DMSO 200㎕로 용해시켜 보라색으로 생성된 포르마잔(formazan)의 양은 살아있는 세포수에 비례하므로 이 양을 정량함으로T 세포 생존율을 측정할 수 있어 모스만(Mosmann)의 방법(문헌 Mosmann, T., Rapid colorimetric assay for the cellular growth and survival. J. Immun. Methods., 65, 55 (1983) 참조)을 변형하여 실시하였다. The cells were cultured in DMEM medium (96 wells, 180 쨉 l) for 2 hours with RAW 264.7 macrophages cultured in DMEM medium and incubated for 24 hours after adding 20 쨉 l of sample. After the incubation, the medium was removed and 200 μl of MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-tetrazolium bromide (Sigma Co., 5 mg / ml in PBS) Further cultured. After 4 hours, the medium was removed, and the amount of formazan produced in purple by dissolving the dark blue crystal formed by mitochondrial dehydrogenase into 200 μl of DMSO, , And thus the T cell survival rate can be measured by quantifying this amount, and the method of Mosmann (Mosmann, T., Rapid colorimetric assay for the cellular growth and survival, J. Immun. (1983)).
RAW 264.7 세포를 배지와 함께 96웰(well)에 180㎕ 넣고 2시간 동안 배양해서 세포가 부착되도록 한 다음, LPS(1㎍/㎖) 20㎕ 및 양성(+) 대조군인 L-NMMA(산화질소 합성 억제제(NO synthesis inhibitory agent))을 포함한 각각의 시료를 20㎕씩 넣고 24시간 배양시켜 LPS(리포폴리사카라이드(lipopolysaccharide))에 의해 산화질소 합성 효소(nitric oxide synthase enzyme)을 발현시켜 생성된 iNOS에 의한 산화질소 생성을 유도한 후, 그리스(Griess) 반응시약(1％ 설파닐아민(sulfanilamine), 0.1％ N-(1-naphthyl)-ethylene diamine dihydrochloride, 2.5％ H3PO4; 시그마사 제품)으로 생성된 산화질소를 이산화질소(NO2)로 산화시켜 이산화질소의 농도를 540㎚에서 흡광도를 측정하고, 질산나트륨(NaNO2)의 검량선을 이용하여 산화질소의 농도를 간접적으로 확인하였다(문헌 Feelisch, M., Stamler, J., Methods in nitric oxide reserch. John Wiley & Sons, 492-497 (1996) 및 Park, S. Y., Hong, S. S., Han, X. H., Ro, J. S., and Hwang, B. Y., Inhibitory Constituents of LPS-induced Nitric oxide Production from Arctium lappa. Natural Product Sciences, 11(2), 85-88 (2005). 참조).RAW 264.7 cells were added to 96 wells in 96 wells and cultured for 2 hours to allow cells to adhere. Then, 20 占 퐇 of LPS (1 占 퐂 / ml) and L-NMMA (positive control (NO synthesis inhibitory agent)) was cultured for 24 hours, and the cells were cultured for 24 hours to express nitric oxide synthase enzyme by LPS (lipopolysaccharide) After the induction of nitric oxide production by iNOS, a Griess reaction reagent (1% sulfanilamine, 0.1% N- (1-naphthyl) -ethylene diamine dihydrochloride, 2.5% H 3 PO 4 , oxidizing the nitrogen oxides generated by the product) to nitrogen dioxide (NO 2) measuring the absorbance, the concentration of nitrogen dioxide in 540㎚, and by using a calibration curve of sodium nitrite (NaNO 2) was confirmed indirectly the concentration of nitrogen oxide (lit. Feelisch, M., Stamler, J., Methods in nitric oxide reserch. Inhibitory Constituents of LPS-Induced Nitric Oxide Production from Arctium lappa. Natural Product Sciences, Kwangwoon University, Seoul, Korea, pp. 492-497 (1996) and Park, SY, Hong, SS, Han, XH, Ro, JS and Hwang, 11 (2), 85-88 (2005)).
실험 결과, 도 1에 나타난 바와 같이, 세포생존율의 경우, 비발효 도라지의 경우, 농도가 증가할수록 급격히 감소하는 경향을 보인 반면 산화질소 억제력도 낮게 나타났다. 그러나 본 발명에 따른 발효 도라지는 생존율이 농도 증가에도 불구하고 오차범위 수준에서 변화가 없는 반면, 농도-의존적으로 산화질소 생성 억제력을 나타내어 항염증효능이 있음을 확인하였다.As a result, as shown in FIG. 1, in the case of cell viability, non-fermented Dorago showed a tendency to decrease rapidly as the concentration increased, but also to suppress nitrogen oxide. However, the fermented Dorrass according to the present invention showed an anti-inflammatory effect due to the concentration-dependent inhibition of nitric oxide production, while the survival rate did not change at the level of the error range despite the increase in the concentration.
실험예 2Experimental Example 2
항산화 활성 측정; DPPH를 이용한 자유 라디칼(free radical) 소거능 측정Antioxidant activity measurement; Measurement of free radical scavenging ability using DPPH
항산화 활성은 안정한 DPPH 자유 라디칼(시그마사 제품)의 소거활성(scavenging activity)에 기초하여 측정하였다. 하타노(Hatano)의 방법(문헌 Hatano, T., Edamatsu, R., Hiramatsu, M., Mori, A., Fujita, Y., Yasuhara, T., Yoshi -da, T. and Okuda, T., Effects of the interaction of tannins with co-exist substances. Ⅳ Effects of tannins and ralated polyphenols on superoxide anion radical, and on 1,1-diphenyl-2- picrylhydrazyl radical. Chem. Pharm. Bull., 37, 2016 (1989). 참조)을 응용하여 각 농도별로 조제한 시료 20㎕에 0.1mM DPPH 용액(99.5％ 에탄올) 180㎕을 가하였다. 10초간 진탕한 후, 37℃에서 30분 동안 인큐베이션(incubation)시킨 후, ELISA 리더(reader)(미합중국 소재 바이오라드사(BIO-RAD) 제품)를 이용하여 517㎚에서 흡광도를 측정하였다. Antioxidant activity was measured based on the scavenging activity of a stable DPPH free radical (Sigma). The method of Hatano (Hatano, T., Edamatsu, R., Hiramatsu, M., Mori, A., Fujita, Y., Yasuhara, T., Yoshi-da, T. and Okuda, T., 37, 2016 (1989), pp. 177-178, 1987. [0008] The present invention relates to a method for the preparation of tannins, , And 180 쨉 l of 0.1 mM DPPH solution (99.5% ethanol) was added to 20 쨉 l of the sample prepared for each concentration. After shaking for 10 seconds, the plate was incubated at 37 ° C for 30 minutes, and absorbance was measured at 517 nm using an ELISA reader (BIO-RAD, USA).
실험 결과, 도 2에 나타난 바와 같이, 버섯균사체 발효 도라지가 비발효 도라지에 비해서 항산화력이 높게 나타남을 확인할 수 있었다. 물과 에탄올 50% 추출물에서는 상대적으로 높게 나타났고, 100% 에탄올 추출물에서도 발효 도라지의 효능이 높게 나타나서 발효 시 항산화력이 증가되는 것을 확인할 수 있었다. 발효 도라지의 항산화 IC50 수준은 물 추출물에서는 42% 수준으로 낮아졌고, 50% 에탄올 추출물에서는 35% 수준으로 낮아졌다. 100% 에탄올 추출물의 경우에는 85% 수준으로 낮아져 물과 50% 에탄올 추출물에 비해 낮은 항산화력 증가를 보여 항산화성 물질이 수용성 물질이 상대적으로 많이 존재함을 알 수 있었다. As a result of the experiment, it was confirmed that the mushroom mycelial fermentation broth showed higher antioxidant power than non-fermented broth, as shown in FIG. Water and
실험예 3Experimental Example 3
본 발명의 실효성을 확인하고 도라지 외에 및/또는 도라지와 함께 근채류 등에의 적용과 균주를 달리한 시험을 위하여 근채류 중 대표적인 인삼을 영지버섯로 발효시킨 것(실시예 3) 및 인삼을 동충하초로 발효시킨 것(실시예 4)의 50% 에탄올 추출물에 대하여 실험예 2 기재와 같은 방법으로 항산화력을 측정하였다.In order to confirm the efficacy of the present invention and to test for the application to the root vegetables other than the bellflower and / or the bellflower and the test with different strains, the representative ginseng of the root vegetables was fermented with Ganoderma lucidum (Example 3) and the ginseng was fermented with the Chinese cabbage The antioxidant activity of the 50% ethanol extract of Example 1 (Example 4) was measured by the same method as described in Experimental Example 2.
실험 결과, 도 4에 나타난 바와 같이, 영지버섯와 동충하초에 의해 발효된 인삼이 비발효 인삼에 비해서 항산화력이 높게 나타남을 확인할 수 있었다. 본 실험에서 50% 에탄올 추출물에서 IC50값은 도라지의 버섯균사체 발효추출물의 50% 에탄올 추출물에 비해서 항산화력이 더 높게 나타남을 확인할 수 있었다. 또한, 비발효 인삼에 비해서 영지버섯으로 발효한 인삼의 경우, 38% 수준으로 낮아졌고, 동충하초로 발효한 인삼의 경우, 역시 57.59% 수준으로 낮아져 인삼 역시 도라지와 같이 버섯균사체를 이용하여 발효시키는 경우, 항산화력이 약 2.65배까지 증가되는 것을 확인할 수 있었다. 인삼의 영지버섯 발효물을 도 5의 좌측 사진에 나타내었고, 인삼의 동충하초 균사체 발효물을 도 5의 우측 사진에 나타내었다.As shown in FIG. 4, the antioxidant activity of ginseng fermented by Ganoderma Lucidum and Cordyceps sinensis was higher than that of non-fermented ginseng. In this experiment, the IC50 value of the 50% ethanol extract was higher than that of the 50% ethanol extract of the mushroom mycelium fermentation extract. In addition, the ginseng fermented with Ganoderma lucidum was lowered to 38% level compared to non-fermented ginseng, and the ginseng fermented with Cordyceps lowers to 57.59%, so that ginseng is also fermented with mushroom mycelium such as bellflower , And the antioxidant capacity was increased to about 2.65 times. 5 shows the left side of the ginseng fermented product of Ganoderma lucidum, and the right side of Fig. 5 shows the fermented product of the ginseng Cordyceps mushroom mycelium.
대식세포는 면역계에서 외부물질 침입을 가장 먼저 인지하고 대식세포의 활성화로 증식과 확산능력의 향상 등과 같은 세포의 형태적 변화뿐만 아니라, 대식능력의 증강, 산화질소(NO) 및 사이토카인(cytokine) 생성의 향상으로 각종 유해인자를 억제시키는 것으로 알려지고 있다. The macrophage is the first to recognize the foreign substance invasion in the immune system, and it not only enhances the morphological changes of the cells such as the enhancement of proliferation and spreading ability by the activation of macrophages but also the enhancement of the macrophage ability, the nitric oxide (NO) and the cytokine It is known that the improvement of production inhibits various harmful factors.
최근 생약재 내의 유효한 성분은 인체의 면역 시스템 중 보체계(complement system)의 활성화, 면역 관련 사이토카인의 활성화 등의 질병에 대한 생체방어 시스템을 보강하는 등 인체의 생체 항상성(homeostasis)에 큰 영향을 미친다고 알려져 있다(문헌 Lee SY. 2000. Use and perspective views of oriental herbs in food industry. Food Ind Nutr 5: 21-26 참조). 일반적으로 염증성 질환에서 산화질소(NO)는 염증성 반응단계의 중요한 매개체(문헌 Nathan et al., 1992 참조)로서, 혈압조절, 신경전달, 혈액응고, 면역기능 등의 역할을 수행하며, 여러 조직과 세포에서 산화질소 합성효소(nitric oxide synthase ; NOS)에 의해 합성되는 것으로 알려져 있다(문헌 Galla et al., 1993 참조). NOS는 단시간 동안 소량의 산화질소를 생성하여 정상적인 생리기능을 담당하며(문헌 Mehta et al., 1995 참조), 대식세포, 내피세포 및 간세포 자극에 활성화되어 다량의 산화질소를 생성하여 종양세포를 죽이거나 미생물 감염방어 등 생체보호 역할을 한다. 그러나 과다한 산화질소는 오히려 쇼크성 혈관확장, 염증반응 유발로 오히려 조직손상 등 유해한 작용을 하게 되는데(문헌 McCartney et al., 1993 참조), 이와 같이 과다하게 생성되는 산화질소의 생성 억제 효능을 가진 물질을 확보하고자 하는 노력이 경주되고 있다. 따라서 본 발명에서는 리포폴리사카라이드(LPS)로 활성화된 RAW 264.7 세포주에서의 산화질소 생성 저해 정도를 확인하므로 항염증성 조절 효과를 확인하였으며, 전체적으로 발효 추출물이 비 발효 추출물에 비해 저해력이 높게 나타남을 확인할 수 있었다. 도라지의 경우, 발효물의 100% 에탄올 추출물에서 저해력이 높게 나타났다. 발효 과정에서 대식세포 RAW264.7의 산화질소 생성능의 억제력에 관여되는 물질들이 다수 생성됨을 확인할 수 있었고, 차후 임상실험을 통해 항염증에 관여되는 물질의 성분 및 기작을 확인할 수 있을 것으로 판단된다. 또한 발효물의 추출 방법에 따른 회수율에 대한 기준도 구체화함으로 산업적 응용 시 원가를 낮춰 경쟁력 높은 상품화가 이루어질 수 있을 것으로 판단된다. Recently, effective ingredients in herbal medicines have greatly influenced the homeostasis of the human body, such as boosting the body defense system against diseases such as activation of the complement system in the human immune system and activation of immune-related cytokines It is known (Lee,
이상에서 본 발명은 기재된 구체예에 대해서만 상세히 설명되었지만 본 발명의 기술사상 범위 내에서 다양한 변형 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속함은 당연한 것이다.While the invention has been shown and described with reference to certain exemplary embodiments thereof, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention as defined by the appended claims.
(도면 부호 없음)(Without reference numerals)
Claims (14)
상기 버섯균사체가 차가버섯, 상황버섯, 꽃송이버섯, 송이버섯, 표고버섯, 잎새버섯, 목이버섯, 새송이버섯, 팽이버섯, 양송이버섯, 구름버섯, 느타리버섯, 영지버섯, 동충하초, 복령, 저령, 치마버섯, 노루궁뎅이버섯으로부터 선택되는 버섯의 균사체들로 이루어지는 군으로부터 선택되는 1종 이상인 것을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물.The method according to claim 1,
The above mushroom mycelium contains a mushroom, a mushroom, a mushroom, a mushroom mushroom, a mushroom mushroom, a mushroom mushroom, a mushroom mushroom, a mushroom mushroom, a mushroom mushroom, a mushroom mushroom, a mushroom mushroom, a mushroom mushroom, a mushroom mushroom, a mushroom mushroom, a mushroom, Mushroom, and mushroom mycelium selected from the group consisting of mushroom, mushroom, and mushroom mycelium selected from the group consisting of mushroom mycelia, and having excellent anti-inflammation and antioxidant activity.
상기 도라지에 오가피, 잔대, 인삼 또는 이들 중 2이상의 혼합물로 이루어지는 군으로부터 선택되는 한약재가 더 포함되는 것을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물.The method according to claim 1,
Wherein the bellflower further comprises a medicinal herb selected from the group consisting of carp, ginger, ginseng, or a mixture of two or more thereof, and has excellent anti-inflammatory and antioxidant activity.
(2) 상기 증자된 도라지를 10 내지 50℃의 범위 이내의 온도까지 냉각시키는 냉각단계; 및
(3) 상기 증자되어 냉각된 도라지 90 내지 99중량%에 버섯균사체 1 내지 10중량%를 접종시키는 접종시킨 후, 15 내지 40℃의 범위 이내의 온도에서 10 내지 30일간 발효시키는 발효단계;
를 포함함을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법.(1) a step of growing the bellflower at a temperature within a range of 90 to 120 캜 for 30 to 90 minutes;
(2) a cooling step of cooling the expanded bellflower to a temperature within a range of 10 to 50 캜; And
(3) a fermentation step of inoculating 1 to 10% by weight of the mushroom mycelia to 90 to 99% by weight of the frozen and cooled broth, followed by fermentation at a temperature within a range of 15 to 40 DEG C for 10 to 30 days;
Wherein the fermented mushroom mycelium has an excellent anti-inflammatory and antioxidant activity.
상기 발효단계에서 상기 버섯균사체가 차가버섯, 상황버섯, 꽃송이버섯, 송이버섯, 표고버섯, 잎새버섯, 목이버섯, 새송이버섯, 팽이버섯, 양송이버섯, 구름버섯, 느타리버섯, 영지버섯, 동충하초, 복령, 저령, 치마버섯, 노루궁뎅이버섯으로부터 선택되는 버섯의 균사체들로 이루어지는 군으로부터 선택되는 1종 이상인 것을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법.5. The method of claim 4,
In the fermentation step, the mycelia of mushrooms are selected from the group consisting of mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, , Mycelium of mushrooms selected from the group consisting of mushroom, mushroom, mushroom, and mushroom. The method for producing the mushroom mycelia fermented composition having excellent anti-inflammatory and antioxidative activity.
상기 도라지에 오가피, 잔대, 인삼 또는 이들 중 2이상의 혼합물로 이루어지는 군으로부터 선택되는 한약재가 더 포함되는 것을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법.5. The method of claim 4,
Wherein the bellflower is further characterized by comprising a medicinal herb selected from the group consisting of carrot, ginseng, ginseng, or a mixture of two or more thereof, and having excellent anti-inflammatory and antioxidant activity.
상기 발효단계 이후에, 상기 발효단계에서 수득되는 발효물을 건조시키는 건조단계를 더 포함함을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법.5. The method of claim 4,
And drying the fermentation product obtained in the fermentation step after the fermentation step, wherein the fermentation product has an excellent anti-inflammatory and antioxidative activity.
상기 건조단계가 동결건조 또는 감압건조 방식으로 수행됨을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법.8. The method of claim 7,
Wherein the drying step is performed by a lyophilization or a vacuum drying method.
상기 발효단계 이후에, 상기 발효단계에서 수득되는 발효물을 물 또는 탄소수 1 내지 4의 저급알코올로 추출하는 추출단계를 더 포함함을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법.5. The method of claim 4,
Wherein the fermentation step further comprises an extraction step of extracting the fermentation product obtained in the fermentation step with water or a lower alcohol having 1 to 4 carbon atoms after the fermentation step, Gt;
상기 추출단계에서 사용되는 저급알코올이 30 내지 100중량%의 알코올을 포함하는 저급알코올임을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법.10. The method of claim 9,
Wherein the lower alcohol used in the extraction step is a lower alcohol containing 30 to 100% by weight of an alcohol, and having excellent anti-inflammatory and antioxidant activity.
상기 추출단계 이후에, 상기 추출단계에서 추출된 추출물을 건조시키는 건조단계를 더 포함함을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법.10. The method of claim 9,
The method of claim 1, further comprising, after the extracting step, drying the extract extracted in the extracting step.
상기 건조단계가 동결건조 또는 감압건조 방식으로 수행됨을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법.12. The method of claim 11,
Wherein the drying step is performed by a lyophilization or a vacuum drying method.
상기 증자단계 이전에 상기 증자될 도라지를 세척하고 건조시키는 전처리단계를 더 포함함을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법.5. The method of claim 4,
And further comprising a pre-treatment step of washing and drying the donor to be donated before the step of donning the donor mushroom mycelial fermentation composition.
상기 냉각단계와 상기 발효단계 사이에서 상기 증자된 도라지를 파쇄하는 파쇄단계를 더 포함함을 특징으로 하는 우수한 항염 및 항산화 활성을 갖는 도라지 버섯균사체 발효 조성물의 제조방법.5. The method of claim 4,
The method of claim 1, further comprising a step of crushing the donated bellflower between the cooling step and the fermentation step.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130121286A KR20150042529A (en) | 2013-10-11 | 2013-10-11 | Fermented ballonflower composition having excellent anti-inflammatory and anti-oxidant activity and manufacturing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130121286A KR20150042529A (en) | 2013-10-11 | 2013-10-11 | Fermented ballonflower composition having excellent anti-inflammatory and anti-oxidant activity and manufacturing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150042529A true KR20150042529A (en) | 2015-04-21 |
Family
ID=53035565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20130121286A KR20150042529A (en) | 2013-10-11 | 2013-10-11 | Fermented ballonflower composition having excellent anti-inflammatory and anti-oxidant activity and manufacturing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20150042529A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170063105A (en) * | 2015-11-30 | 2017-06-08 | 전북대학교산학협력단 | Fermentation Method for Increasing Content of Total Phenolic Compounds and -Glucan with Solid Fermented Doraji Platycodon grandiflorum using mushroom mycelia |
| KR20170084688A (en) * | 2016-01-11 | 2017-07-20 | 재단법인 전주농생명소재연구원 | Composition for preventing, improving and treating atopic dermatitis comprising ginseng berry extract fermented using Hericium erinaceum mycelium as effective component |
| KR20190027179A (en) * | 2017-09-06 | 2019-03-14 | 주식회사 아미코스메틱 | A cosmetic composition comprising arenaria serpyllifolia extract |
| KR20190027177A (en) * | 2017-09-06 | 2019-03-14 | 주식회사 아미코스메틱 | A cosmetic composition comprising juniperus chinensis var. sargentii extract |
| KR20190027178A (en) * | 2017-09-06 | 2019-03-14 | 주식회사 아미코스메틱 | A cosmetic composition comprising centipeda minima extract |
| KR20190059628A (en) * | 2017-11-23 | 2019-05-31 | 농업회사법인 주식회사 모이식품 | Fermented balloon flower using detoxicating, fermenting and steaming process and manufacturing method thereof |
| KR20200013327A (en) * | 2018-07-30 | 2020-02-07 | 대구한의대학교산학협력단 | Food composition for anti-oxidant and anti-inflammatory comprising extract of fermented soybean and preparation method thereof |
| KR20210026739A (en) | 2019-09-02 | 2021-03-10 | 한도라지영농조합법인 | Method for preparing bellflower root powder containing bellflower root extract as active ingredient |
| KR20210045142A (en) * | 2019-10-16 | 2021-04-26 | 대한민국(농촌진흥청장) | Composition for anti-oxidant and anti-inflammation comprising bellflower sprout extract |
| KR20210110924A (en) * | 2020-03-02 | 2021-09-10 | 농업회사법인주식회사 오상킨섹트 | White spotted flower larva larvae feed composition using coffee foil |
-
2013
- 2013-10-11 KR KR20130121286A patent/KR20150042529A/en not_active Application Discontinuation
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170063105A (en) * | 2015-11-30 | 2017-06-08 | 전북대학교산학협력단 | Fermentation Method for Increasing Content of Total Phenolic Compounds and -Glucan with Solid Fermented Doraji Platycodon grandiflorum using mushroom mycelia |
| KR20170084688A (en) * | 2016-01-11 | 2017-07-20 | 재단법인 전주농생명소재연구원 | Composition for preventing, improving and treating atopic dermatitis comprising ginseng berry extract fermented using Hericium erinaceum mycelium as effective component |
| KR20190027179A (en) * | 2017-09-06 | 2019-03-14 | 주식회사 아미코스메틱 | A cosmetic composition comprising arenaria serpyllifolia extract |
| KR20190027177A (en) * | 2017-09-06 | 2019-03-14 | 주식회사 아미코스메틱 | A cosmetic composition comprising juniperus chinensis var. sargentii extract |
| KR20190027178A (en) * | 2017-09-06 | 2019-03-14 | 주식회사 아미코스메틱 | A cosmetic composition comprising centipeda minima extract |
| KR20190059628A (en) * | 2017-11-23 | 2019-05-31 | 농업회사법인 주식회사 모이식품 | Fermented balloon flower using detoxicating, fermenting and steaming process and manufacturing method thereof |
| KR20200013327A (en) * | 2018-07-30 | 2020-02-07 | 대구한의대학교산학협력단 | Food composition for anti-oxidant and anti-inflammatory comprising extract of fermented soybean and preparation method thereof |
| KR20210026739A (en) | 2019-09-02 | 2021-03-10 | 한도라지영농조합법인 | Method for preparing bellflower root powder containing bellflower root extract as active ingredient |
| KR20210045142A (en) * | 2019-10-16 | 2021-04-26 | 대한민국(농촌진흥청장) | Composition for anti-oxidant and anti-inflammation comprising bellflower sprout extract |
| KR20210110924A (en) * | 2020-03-02 | 2021-09-10 | 농업회사법인주식회사 오상킨섹트 | White spotted flower larva larvae feed composition using coffee foil |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20150042529A (en) | Fermented ballonflower composition having excellent anti-inflammatory and anti-oxidant activity and manufacturing method thereof | |
| Song et al. | Progress on understanding the anticancer mechanisms of medicinal mushroom: Inonotus obliquus | |
| KR100962587B1 (en) | A method for fermentation of natural plants and herbal medicines, a fermented product prepared therefrom and a paharmaceutical composition, a cosmetic compositon and a food composition comprising the product | |
| KR20080094459A (en) | Cosmetic composition having antioxidation activity | |
| KR20090002678A (en) | Cosmetic composition for preventing of kin trouble | |
| KR101423573B1 (en) | Cosmetic composition having antioxidation activity | |
| KR20090123458A (en) | A method for fermentation of natural plants or herbal medicines, a fermented product prepared therefrom and a cosmetic composition, a food composition and a pharmaceutical composition comprising the same | |
| KR101867308B1 (en) | Cosmetic composition comprising Hydrangea macrophylla fermented extract for alleviating skin irritation and alleviating skin inflammation | |
| KR101412500B1 (en) | Cosmetic composition for improving atopic skin comprising herb extract fermented in bamboo cylinder and manufacturing method thereof | |
| KR101431417B1 (en) | The method of oriental composite for treatment of atopy and cancer | |
| KR102004366B1 (en) | A cosmetic composition comprising centipeda minima extract | |
| KR101397160B1 (en) | Cosmetic compositon for skin-irritation alleviation with Inula britannica var. chinensis, Cynanchi Radix and Lysimachia foenum-graecum Hance | |
| KR102174660B1 (en) | Cosmetic Composition Comprising Fermented Liquor and Powder of Natural Plant and Preparation Methods Thereof | |
| KR101167295B1 (en) | A cosmetic composition for skin-antiaging effect comprising of oriental medical herbs' extracts fermened and method for preparing the same | |
| KR101980887B1 (en) | A cosmetic composition comprising trichosanthes kirilowii extract and metaplexis japonica extract | |
| KR102176938B1 (en) | Cosmetic Composition Comprising Fermented Liquor of Natural Plant and Preparation Methods Thereof | |
| KR100981344B1 (en) | The cosmetic composition for preventing the skin aging | |
| KR20200042657A (en) | The skin cosmetic composition for anti-oxidation and anti-inflammation of skin comprising natural complex extracts | |
| KR102181220B1 (en) | Pharmaceutical composition for anti-cancer containing medicinal gerb extracts | |
| CN112137919A (en) | Beauty external product or edible product based on bamboo fungus egg extract and application | |
| KR102507651B1 (en) | Fermented Stauntonia hexaphylla for hangover relief, alcoholic liver disease or liver function improvement using fermented enzyme complex solution containing traditional brewery yeast and its manufacturing method | |
| KR101521753B1 (en) | Cosmetic composition having antioxidation activity | |
| KR20150073438A (en) | Method for preparing fermented extract of Salvia miltiorrhiza Bunge by using of microorganism | |
| KR101521752B1 (en) | Cosmetic composition having antioxidation activity | |
| KR101521754B1 (en) | Cosmetic composition having antioxidation activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E601 | Decision to refuse application |